Bibliography for Topic 2: Clinical Development of Influenza Vaccines for Pre-pandemic Preparedness.
 Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG. Characterization of the 1918 influenza virus polymerase genes. Nature 2005;437:889-893.
2 Tumpey TM, Basler CF, Aguilar PV, et al. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science. 2005;310:77-80.
3 Claas ECJ, Osterhaus ADME, van Geck R, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. The Lancet 1998;351:472-477.
4 Ungchusak K, Auewarakul P, Dowell, et al. Probable person-to-person transmission of avian influenza A (H5N1). NEJM 2005;352:333-340.
5 The World Health Organization: Epidemic and Pandemic Alert and Response, which can be found on the World Wide Web at: www.who.int/csr/disease/avian_influenza/country/en/index.html
6 Englund JA, Walter EB, Fairchok MP,
7 Walter EB, Neuzil KM, Zhu Y, et al. Influenza vaccine immunogenicity in 6- to 23- month-old children: are identical antigens necessary for priming? Pediatrics 2006;118:570-578.
8 Department of Health and Human Services, NIH News. “Preliminary Results Suggest Priming Boosts Immune Responses to Variant H5N1 Vaccine”, which can be found on the World Wide Web at: http://www.nih.gov/news/pr/oct2006/niaid-12b.htm
9 Couch RB, Kasel JA. Immunity to influenza in man. Annu. Rev. Microbiol. 1983;37:529-549.
G, Eickoff TC,
2 Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF-59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. JID 2005;191:000-000.
3 Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55:1-41 and can be found on the World Wide Web at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr55e628a1.htm